Skip to main content
Get the Weekly ESG Brief

Charles River Laboratories International, Inc.

CRLNYSETrackedESG Rated: 1/2 ProvidersMarket Data VerifiedHealth CareLife Sciences Tools And ServicesMSCI: 71.1 / 100

Coverage
Rated universe Carries an MSCI or Sustainalytics observation.
ESG profile reviewed
Last editorial update to this profile.
Quote
Delayed quoteObservation time is shown beside the price.
Methodology
How we rateProvider ratings are shown separately, never blended.

Market overview

USD 293.79

Up+USD 16.46 (+5.94%) Day change

Delayed quote · As of · USD · Market data via Massive Stock Widgets

This quote can lag the exchange by several minutes. It is not a real-time price.

Open
USD 277.00
Previous close
USD 277.33
Day high
USD 298.23
Day low
USD 277.00
Volume
717,198
Market cap
USD 14,151,197,696
Price chart · 1 Year
Charles River Laboratories International, Inc. 1 Year price chartCharles River Laboratories International, Inc., nyse:CRL, 1 Year price chart in USD. Start USD 150.25, end USD 279.01, high USD 298.58, low USD 145.57, up.
Period1 YearFirst closeUSD 150.25Last closeUSD 279.01Maximum closeUSD 298.58Minimum closeUSD 145.57Period change+USD 128.76Period percentage change+85.70%Chart as ofSep 21, 2026, 1:30 PM GMT+0000
View Chart Data
Representative chart points — 24 of 250
Date and time Open High Low Close Volume
USD 154.22 USD 154.94 USD 149.91 USD 150.25 786,800
USD 148.39 USD 148.39 USD 144.26 USD 145.57 884,200
USD 167.72 USD 175.00 USD 165.70 USD 170.88 1,906,800
USD 163.59 USD 172.39 USD 157.49 USD 167.64 1,342,700
USD 186.80 USD 191.34 USD 185.93 USD 185.99 1,070,100
USD 202.69 USD 204.01 USD 201.04 USD 203.16 242,000
USD 221.22 USD 222.29 USD 213.46 USD 218.82 743,900
USD 218.45 USD 219.37 USD 214.48 USD 216.88 444,600
USD 183.06 USD 183.11 USD 162.95 USD 165.98 1,979,600
USD 172.08 USD 179.82 USD 170.00 USD 178.49 1,198,300
USD 157.67 USD 158.51 USD 151.68 USD 151.97 791,000
USD 162.55 USD 172.57 USD 162.04 USD 172.50 1,180,100
USD 178.94 USD 185.00 USD 175.79 USD 176.94 915,100
USD 167.66 USD 167.66 USD 163.10 USD 165.78 668,800
USD 157.54 USD 160.26 USD 149.98 USD 150.85 1,397,500
USD 179.00 USD 181.76 USD 172.17 USD 174.79 752,100
USD 188.81 USD 191.34 USD 181.72 USD 182.34 1,025,200
USD 227.59 USD 232.32 USD 223.85 USD 231.43 631,900
USD 215.57 USD 223.62 USD 213.40 USD 219.40 925,000
USD 267.99 USD 267.99 USD 252.07 USD 260.72 1,782,400
USD 284.22 USD 294.56 USD 280.68 USD 290.00 987,400
USD 297.63 USD 299.02 USD 290.73 USD 298.58 786,100
USD 294.21 USD 295.77 USD 285.56 USD 293.35 646,300
USD 279.37 USD 281.63 USD 275.88 USD 279.01 952,900

Company Profile & Business Model Overview

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.

Sustainability Strengths & Catalysts (Pros)

  • Extensive animal welfare policies and investment in alternative methods: CRL publishes animal care and use policies, works to implement the 3Rs (replacement, reduction, refinement), and invests in non-animal technologies and in vitro models to reduce reli
  • Global compliance and quality management infrastructure: CRL maintains broad regulatory compliance programs and quality management systems across many international sites, supporting client requirements for GLP/GCP standards and biosafety practices that h
  • Environmental management and emissions reporting initiatives: CRL has set company-level environmental goals and reports on energy use, greenhouse gas emissions, and waste management in sustainability disclosures, with site-level actions to improve energy

Material Risks & Governance Concerns (Cons)

  • Animal testing and ethical controversies: As a major contract research organization providing extensive animal testing and breeding services, CRL faces ongoing ethical scrutiny and reputational risk from animal welfare groups and stakeholders opposed to a
  • Operational and environmental risks from laboratory activities: CRL’s global laboratory footprint entails risks related to hazardous waste, chemical and biological materials handling, and potential regulatory lapses or incidents at sites that could result

Related ESG Peer Equities

Companies in Health Care evaluated across carbon intensity, social metrics, and board governance.

Explore Health Care Peers →

ESG & Sustainability Rating Breakdown

Synthesized multi-provider rating across Environmental, Social, and Corporate Governance dimensions.

Audited Methodology

MSCI ESG Rating

71.1 / 100

MSCI ESG industry rating benchmark.

Sustainalytics Risk Score

N/A

Data integrity and methodology

MSCI and Sustainalytics ratings are shown separately with their own observation dates; they are not blended into one score, and providers can disagree. Market quotes are delayed or last-close values, and every snapshot states its source and observation time. Read the full rating methodology.

FAQ

Frequently Asked Questions

Direct answers on sustainability scores, risk methodologies, and peer rankings.

What is Charles River Laboratories International, Inc. (CRL)'s ESG rating and sustainability score?

Charles River Laboratories International, Inc. (CRL) has an MSCI ESG rating of 71.1 / 100. MSCI evaluates corporate resilience to long-term industry material environmental, social, and governance risks relative to sector peers.

Is Charles River Laboratories International, Inc. considered an ESG leader or laggard in Health Care?

Independent benchmark status for Charles River Laboratories International, Inc. is evaluated relative to Health Care peers once third-party coverage publishes official methodology scores.

What are the main ESG risks and controversies for Charles River Laboratories International, Inc.?

Key material risks for Charles River Laboratories International, Inc. include: Animal testing and ethical controversies: As a major contract research organization providing extensive animal testing and breeding services, CRL faces ongoing ethical scrutiny and reputational risk from animal welfare groups and stakeholders opposed to a; Operational and environmental risks from laboratory activities: CRL’s global laboratory footprint entails risks related to hazardous waste, chemical and biological materials handling, and potential regulatory lapses or incidents at sites that could result. Investors should evaluate whether corporate mitigation plans adequately address these vulnerabilities.

How does The Impact Investor evaluate ESG stock profiles?

The Impact Investor presents audited third-party ratings from MSCI and Sustainalytics alongside delayed market data and financial fundamentals. We do not blend ratings into proprietary black-box scores, and ratings are never modified by advertising or affiliate relationships.